SLS - CIK 0001390478
SELLAS Life Sciences Group, Inc. trades as SLS and has a market capitalization of $1.33 B, making it the #2422 largest US-listed company by market value. In its fiscal 2023 annual report the company posted revenue of $0.00, down 100.0% from the prior year and net income of -$26.86M. This page tracks SELLAS Life Sciences Group, Inc. through 1,262 SEC filings, with financial statements and metrics updated as new reports are filed.
Net profit margin compressed from -881.9% to -4130.1% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-12 |
| Quarterly report | 10-Q | 2026-05-12 |
| SCHEDULE 13G/A | - | 2026-04-24 |
| Annual report to shareholders | ARS | 2026-04-23 |
| Proxy materials | DEFA14A | 2026-04-23 |
| Proxy statement | DEF 14A | 2026-04-23 |
| SCHEDULE 13G/A | - | 2026-03-27 |
| S-3ASR | - | 2026-03-20 |
**Format:** Corporate Presentation and Fireside Chat
_– Final Analysis of REGAL Trial of GPS in AML to be Conducted Following the 80_ _th_ _Event –_
_– Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 Events –_
\- Preclinical data show that SLS009 lowers the apoptotic threshold in AML cells by suppressing critical survival pathways -
_\- Study to Enroll 80 Patients Unlikely to Benefit from Venetoclax/Azacitide (Aza/Ven) Therapy in the US and Europe -_ _\- SELLAS’ Predictive Biomarker and AI Assisted Precision Medicine Models to be Utilized -_
The largest companies sharing SELLAS Life Sciences Group, Inc.'s SEC industry classification (pharmaceutical preparations).
SELLAS Life Sciences Group, Inc. (SLS) has a market capitalization of $1.33 B as of 2026-06-10, ranking #2422 among US-listed companies.
SELLAS Life Sciences Group, Inc. reported revenue of $0.00 for fiscal year 2023, a decrease of 100.0% year over year.
In its latest fiscal year SELLAS Life Sciences Group, Inc. reported a net loss of $26.86M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.